Coralie Reger de Moura

Dr. Coralie Reger de Moura

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2019 in Cancers
Verified
Journal Article
Open access
PDF file
ALAlexandra Landras
Alexandra Landras
CMCoralie Reger de Moura
Coralie Reger de Moura
FJFanelie Jouenne
Fanelie Jouenne
Céleste LebbéCéleste Lebbé
Céleste Lebbé
SMSuzanne Menashi
Suzanne Menashi
Samia MourahSamia Mourah
Samia Mourah
Microenvironment plays a crucial role in tumor development and progression. Cancer cells modulate the tumor microenvironment, which also contribute to resistance to therapy. Identifying biomarkers involved in tumorigenesis and cancer progression represents a great challenge for cancer diagnosis and therapeutic strategy development. CD147 is a glycoprotein involved in the regulation of the tumor microenvironment and cancer progression by several mechanisms—in particular, by the control of glycolysis and also by its well-known ability to induce proteinases leading to matrix degradation, tumor cell invasion, metastasis and angiogenesis. Accumulating evidence has demonstrated the role of CD147 expression in tumor progression and prognosis, suggesting it as a relevant tumor biomarker for cancer diagnosis and prognosis, as well as validating its potential as a promising therapeutic target in cancers.

24 May 2023 in Cancers
Verified
Journal Article
Open access
PDF file
JDJulie Delyon
Julie Delyon
AVAnaïs Vallet
Anaïs Vallet
MBMélanie Bernard-Cacciarella
Mélanie Bernard-Cacciarella
IKIsabelle Kuzniak
Isabelle Kuzniak
CMCoralie Reger de Moura
Coralie Reger de Moura
Nicolas DumazNicolas Dumaz
Nicolas Dumaz
Because BRAF-mutated melanomas are addicted to the Mitogen Activated Protein Kinase (MAPK) pathway they show a high response rate to BRAF and MEK inhibitors. However, the clinical responses to these inhibitors are often short-lived with the rapid onset of resistance to treatment. Deciphering the molecular mechanisms driving resistance has been the subject of intense research. Recent in vitro and clinical data have suggested a link between expression of telomerase and resistance to targeted therapy in melanoma. TERT promoter mutations are the main mechanism for the continuous upregulation of telomerase in melanoma and co-occur frequently with BRAF alterations. To understand how TERT promoter mutations could be associated with resistance to targeted therapy in melanoma, we conducted translational and in vitro studies. In a cohort of V600E-BRAF-mutated melanoma patients, we showed that the TERT promoter mutation status and TERT expression tended to be associated with response to BRAF and MEK inhibitors. We demonstrated that TERT overexpression in BRAF-mutated melanoma cells reduced sensitivity to BRAF and MEK independently of TERT’s telomer maintenance activity. Interestingly, inhibition of TERT reduced growth of BRAF-mutated melanoma including resistant cells. TERT expression in melanoma can therefore be a new biomarker for resistance to MAPK inhibitors as well as a novel therapeutic target.

26 February 2022 in Oncogene
Verified
Journal Article
Closed access
PDF file
ALAlexandra Landras
Alexandra Landras
CMCoralie Reger de Moura
Coralie Reger de Moura
Bruno VilloutreixBruno Villoutreix
Bruno Villoutreix
MBMaxime Battistella
Maxime Battistella
ASAurélie Sadoux
Aurélie Sadoux
Samia MourahSamia Mourah
Samia Mourah

28 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
CMCoralie Reger de Moura
Coralie Reger de Moura
ALAlexandra Landras
Alexandra Landras
FKFarah Khayati
Farah Khayati
UMUwe MASKOS
Uwe MASKOS
KMKamel Maouche
Kamel Maouche
Samia MourahSamia Mourah
Samia Mourah
Malignant melanoma is one of the most aggressive skin cancers and is characterized by early lymph node metastasis and the capacity to develop resistance to therapies. Hence, understanding the regulation of lymphangiogenesis through mechanisms contributing to lymphatic vessel formation represents a treatment strategy for metastatic cancer. We have previously shown that CD147, a transmembrane glycoprotein overexpressed in melanoma, regulates the angiogenic process in endothelial cells. In this study, we show a correlation between high CD147 expression levels and the number of lymphatic vessels expressing LYVE-1, Podoplanin, and VEGFR-3 in human melanoma lymph nodes. CD147 upregulates in vitro lymphangiogenesis and its related mediators through the PROX-1 transcription factor. In vivo studies in a melanoma model confirmed that CD147 is involved in metastasis through a similar mechanism as in vitro. This study, demonstrating the paracrine role of CD147 in the lymphangiogenesis process, suggests that CD147 could be a promising target for the inhibition of melanoma-associated lymphangiogenesis.

18 August 2019 in Cancers
Verified
Journal Article
Open access
PDF file
BLBaptiste Louveau
Baptiste Louveau
FJFanelie Jouenne
Fanelie Jouenne
CMCoralie Reger de Moura
Coralie Reger de Moura
ASAurelie Sadoux
Aurelie Sadoux
Barouyr BaroudjianBarouyr Baroudjian
Barouyr Baroudjian
Samia MourahSamia Mourah
Samia Mourah
In BRAFV600mut metastatic melanoma, the combination of BRAF and MEK inhibitors (BRAFi, MEKi) has undergone multiple resistance mechanisms, limiting its clinical benefit and resulting in the need for response predicting biomarkers. Based on phase III clinical trial data, several studies have previously explored baseline genomic features associated with response to BRAFi + MEKi. Using a targeted approach that combines the examination of mRNA expression and DNA alterations in a subset of genes, we performed an analysis of baseline genomic alterations involved in MAPK inhibitors’ resistance in a real-life cohort of BRAFV600mut metastatic melanoma patients. Twenty-seven patients were included in this retrospective study, and tumor samples were analyzed when the BRAFi + MEKi therapy was initiated. The clinical characteristics of our cohort were consistent with previously published studies. The BRAFi + MEKi treatment was initiated in seven patients as a following-line treatment, and had a specific transcriptomic profile exhibiting 14 genes with lower mRNA expression. However, DNA alterations in CCND1, RB1, and MET were only observed in patients who received BRAFi + MEKi as the first-line treatment. Furthermore, KIT mRNA expression was significantly higher in patients showing clinical benefit from the combined therapy, emphasizing the tumor-suppressor role of KIT already described within the context of BRAF-mutant melanoma.

3 April 2024 in Oncogene
Verified
Journal Article
Closed access
PDF file
CMCoralie Reger de Moura
Coralie Reger de Moura
BLBaptiste Louveau
Baptiste Louveau
FJFanélie Jouenne
Fanélie Jouenne
PVPaul Vilquin
Paul Vilquin
Maxime BattistellaMaxime Battistella
Maxime Battistella
Samia MourahSamia Mourah
Samia Mourah